JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $26
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.
JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and raises the price target from $23 to $26.